BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
glucose metabolic process
,
Obesity
,
Stem cell
,
Metabolism of nitric oxide
,
SNCA
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
mapk1 protein, human
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Bronchial epithelial S9 and 16HBE14o- cells in response to staphylococcal alpha-toxin treatment
HLA-B27 positive monocytes stimulated with Vibrio cholerae lipopolysaccharide
ER+ breast tumors from patients with early, intermediate or late breast cancer recurrence
Explore Curated Studies Results
Literature
Most Relevant Literature
Tumor-suppressive miR-29c binds to MAPK1 inhibiting the ERK/MAPK pathway in pancreatic cancer.
Identification of a novel target site for ATP-independent ERK2 inhibitors.
Hsa_circ_0020378 targets miR-556-5p/MAPK1 to regulate osteosarcoma cell proliferation and migration.
Silencing circCAMSAP1 suppresses malignant behavior of endometrial cancer by targeting microRNA-370-…
miR-92a-1-5p enriched prostate cancer extracellular vesicles regulate osteoclast function via MAPK1 …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
RASopathy Biorepository
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ